Navigation Links
inVentiv Health to Announce First Quarter 2009 Results and Conduct Conference Call on Friday, May 8
Date:4/15/2009

SOMERSET, N.J., April 15 /PRNewswire-FirstCall/ -- inVentiv Health, Inc. (Nasdaq: VTIV) today announced that it will release its First Quarter 2009 results and conduct a conference call on Friday, May 8, 2009 at 8:30 a.m. Eastern Time.

Conference Call Details

To listen, please dial 800-358-8448 (Domestic) or (706) 634-1367 (International). The conference call also will be webcast live on the Internet at http://www.inventivhealth.com/about_us/n_webcasts.aspx. To listen, please go to the site at least 15 minutes in advance of the call to register, download and install any necessary audio software.

An archived audio webcast of the presentation can be accessed by logging on to http://www.inventivhealth.com/about_us/n_webcasts.aspx, and a replay of the call will be available immediately following the call through May 15, 2009 at 800-642-1687. The conference ID number for the replay is 95518884.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payer companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
9. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):